U.S. markets close in 6 hours 2 minutes
  • S&P 500

    4,074.27
    -2.33 (-0.06%)
     
  • Dow 30

    33,961.61
    -124.43 (-0.37%)
     
  • Nasdaq

    11,586.50
    +1.95 (+0.02%)
     
  • Russell 2000

    1,930.82
    -1.13 (-0.06%)
     
  • Crude Oil

    78.72
    -0.15 (-0.19%)
     
  • Gold

    1,944.00
    -1.30 (-0.07%)
     
  • Silver

    23.75
    -0.09 (-0.38%)
     
  • EUR/USD

    1.0908
    +0.0041 (+0.38%)
     
  • 10-Yr Bond

    3.4860
    -0.0430 (-1.22%)
     
  • GBP/USD

    1.2343
    +0.0026 (+0.21%)
     
  • USD/JPY

    129.3490
    -0.7190 (-0.55%)
     
  • BTC-USD

    23,130.86
    -33.50 (-0.14%)
     
  • CMC Crypto 200

    524.11
    +281.43 (+115.97%)
     
  • FTSE 100

    7,780.44
    +8.74 (+0.11%)
     
  • Nikkei 225

    27,346.88
    +19.77 (+0.07%)
     

Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy

  • Evaxion Biotech A/S (NASDAQ: EVAX) has announced interim safety and immunogenicity data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.

  • In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma.

  • "We are thrilled to announce promising interim data from the first eight patients...All patients demonstrated a specific T-cell immune response induced by the treatment, confirming the potential capabilities of our AI platform technology," said CEO Per Norlén.

  • Personalized cancer immunotherapy, like EVX-02, is particularly challenging to produce because a new and unique drug is manufactured for each patient.

  • The treatment appeared to be well tolerated in all patients, with only very mild adverse events (AEs) observed in relation to EVX-02 treatment.

  • EVX-02 induced CD4+ and CD8+ specific T-cell responses in all patients, providing proof of mechanism for DNA-delivery technology, in that the delivered EVX-02-DNA gave rise to immune reactions to its encoded neoantigen peptides. The T-cell responses were robust and long-lasting.

  • A full clinical trial report for the EVX-02 Phase 1 study is expected in the second quarter of 2023.

  • Price Action: EVAX shares traded higher by 0.92% at $2.24 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.